Class summary at a glance.

Every drug in the Antirheumatic Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $69.9Mcombined across class
Total Rx claims: 875K273K unique beneficiaries
Generic mfrs (active): 17across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Leflunomide

Brand: Arava · 873K Part D claims (CY24) · 272K beneficiaries · First FDA approval: 1998-09-10

9 generic mfrs 0 plans require PA

Low NADAC$0.288

→

Avg plan cost$0.309

Part D spend $54.0M 1× spread, current vs floor

Class share

77%

of class CY24 spend

View profile →

Penicillamine

Brand: AAGYLUR · 2K Part D claims (CY24) · 434 beneficiaries · First FDA approval: 1970-12-04

8 generic mfrs 102 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $15.9M

Class share

23%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.